Rinvoq ER 30 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FEGYG
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,140
Award facts
- Contract value 100% obligated
- $13,140.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $13.14K to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, representing part of the broader pharmaceutical supply chain supporting federal healthcare needs.
This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated SPE2DX, which carries a $1 billion ceiling and extends through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant federal contracting portfolio with the DLA and serves critical customers including the Defense Health Agency and U.S. Coast Guard through competitively awarded, firm fixed-price delivery mechanisms across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DB25FEGYG?
SPE2DB25FEGYG was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 28, 2025.
How much is contract SPE2DB25FEGYG worth?
The government has obligated $13,140 on SPE2DB25FEGYG.
Is contract SPE2DB25FEGYG an order under another contract?
Yes. SPE2DB25FEGYG is a delivery order under SPE2DB24D2205, an indefinite delivery contract.
Was contract SPE2DB25FEGYG competed?
The extent of competition for SPE2DB25FEGYG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award